British BTG claims that its subsidiary Provensis the company of the two pilot studies show that their new micro-bubble VarisolveR safe and effective treatment of varicose veins. Test in England and the South Manchester University A Boding Royal Hospital. Originally prepared for surgical treatment of 41 patients with moderate to severe varicose veins patients involved in the study, patients within one week to accept one or two injections of the drug treatment, all patients with the treatment the same day or the next day that is able to resume normal work. B-examination to show that the narrow varicose veins and venous flow of the abnormal blood-flow as vanish success criteria, the total efficiency of 81%, and the effect of a surgical method. The United States and Europe have more than 150 million patients with severe varicose veins in each of 4 million new patients. Manchester study for Dr. Charles McCollum of Varisolve method is full of confidence that as long as a suitable treatment of doctors, equipment and technology, external use this method in the hospital to the treatment of patients with varicose veins are obvious, but very little discomfort. Efficacy and surgical methods rather, do not produce scars healing without pain. Researchers believe, VarisolveR satisfied with the effect of therapy, from time to patient treatment, is expected to replace surgery to treat varicose veins.
